Welcome to the e-CCO Library!

P439 Patient’ recruitment for a Phase 3 inflammatory bowel disease (IBD) programme is significantly increased when accessing the CT-SCOUT™ platform
Year: 2020
Source:

ECCO'20 Vienna

Authors:

Y. Bouhnik1, X. Roblin2, R. Mrad3, X. Hebuterne4, D. Laharie5, C. Tanasa Stefanescu1, S. Nancey6, A. Boureille7, A. Amiot8, N. Sebbah9, L. Peyrin Biroulet10

Created: Thursday, 30 January 2020, 10:12 AM
P439: Diagnosis and management of latent and active tuberculosis in the context of biologic therapy in inflammatory bowel disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Thi A.A.*1, Bouri S.1, Wolfson P.1, Owen L.1, Abbara A.2, John L.2, Davidson R.2, Hart A.1

Created: Wednesday, 20 February 2019, 10:36 AM
P439: Effectiveness and safety of the sequential use of a second and third anti-TNF agent in patients with inflammatory bowel disease: results from the ENEIDA registry
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. J. Casanova*1, M. Chaparro1, M. Mínguez2, E. Ricart3, C. Taxonera4, S. García-López5, J. Guardiola6, A. López-San Román7, E. Iglesias8, B. Beltrán9, B. Sicilia10, M. I. Vera11, J. Hinojosa12, S. Riestra13, E. Domènech14, X. Calvet15, J. L. Pérez-Calle16, M. D. Martín-Arranz17, X. Aldeguer18, M. Rivero19, D. Monfort20, J. Barrio21, M. Esteve22, L. Márquez23, R. Lorente24, E. García-Planella25, L. de Castro26, F. Bermejo27, O. Merino28, A. Rodríguez-Pérez29, P. Martínez-Montiel30, M. Van Domselaar31, G. Alcaín32, M. Domínguez-Cajal33, C. Muñoz34, F. Gomollón35, L. Fernández-Salazar36, M. F. García-Sepulcre37, I. Rodríguez-Lago38, A. Gutiérrez39, F. Argüelles-Arias40, C. Rodriguez41, G. E. Rodríguez42, L. Bujanda43, J. Llaó44, P. Varela45, L. Ramos46, J. M. Huguet47, P. Almela48, P. Romero49, M. Navarro-Llavat, Á. Abad, P. Ramírez-de la Piscina, A. J. Lucendo, E. Sesé, R. E. Madrigal, M. Charro, A. García-Herola, R. Pajares, S. Khorrami, J. P. Gisbert1

Created: Friday, 22 February 2019, 9:41 AM
P439: Effectiveness of a training programme on motivational interviewing skills applied to inflammatory bowel disease management
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

M. Daperno*1, F. Mocciaro2, F. Caprioli3, M. Fantini4, S. Leone5, M. Comberlato6, V. Quercia7

Created: Friday, 22 February 2019, 9:49 AM
P439: Effectiveness of Ustekinumab on Crohn's disease associated spondyloartropathy: real-world data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)
Year: 2021
Source: ECCO'21 Virtual
Authors: Macaluso, F.(1);Fries, W.(2);Viola, A.(2);Costantino, G.(2);Muscianisi, M.(2);Cappello, M.(3);Guida, L.(3);Giuffrida, E.(3);Magnano, A.(4);Pluchino, D.(4);Ferracane, C.(4);Magrì, G.(5);Di Mitri, R.(6);Mocciaro, F.(6);Privitera, A.C.(7);Camilleri, S.(8);Garufi, S.(8);Renna, S.(1);Casà, A.(1);Scrivo, B.(1);Ventimiglia, M.(1);Orlando, A.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P439: Induction of endoscopic response, remission and ulcer-free endoscopy with upadacitinib is associated with improved quality of life in patients with Crohn's disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Panés, J.(1)*;Louis, E.(2);Bossuyt, P.(3);Joshi, N.(4);Lee, W.J.(4);Lacerda, A.(4);Remple, V.(4);Xuan, S.(4);Loftus Jr. , E.V.(5);
Created: Friday, 14 July 2023, 11:05 AM
P439: Monitoring inflammatory Bowel disease activity in a virtual biologic clinic: The effects of proactive therapeutic drug monitoring on patient reported outcome measures
Year: 2018
Source: ECCO '18 Vienna
Authors:

N. Mc Gettigan*, M. McNally, C. Deane, A. Keogh, R. Costello, E. Slattery

Created: Thursday, 21 February 2019, 9:14 AM
P439: Stability of subcutaneous serum IFX (CTP13) levels between two injections and over two successive cycles in patients with Crohn's disease.
Year: 2022
Source: ECCO'22
Authors: Roblin, X.(1);Bastide, L.(1);veyrard, P.(1);berger, A.E.(2);Paul, S.(2);
Created: Friday, 11 February 2022, 3:52 PM
P440 Polimedication in patients with inflammatory bowel disease: prevalence and outcomes in a retrospective unicentric series
Year: 2020
Source:

ECCO'20 Vienna

Authors:

F. Mesonero Gismero, C. Fernández, E. Sánchez-Rodríguez, A. García-García de Paredes, A. Albillos, A. López-Sanromán

Created: Thursday, 30 January 2020, 10:12 AM
P440: Comparison of infliximab serum levels between venous and capillary blood in paediatric IBD patients using novel blood sampling technology
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. Zijlstra*1, M. Jongsma2, A. de Vries3, T. Schaap3, K. Bloem3, L. de Ridder2

Created: Friday, 22 February 2019, 9:41 AM
P440: Early changes in the pharmacokinetic profile of vedolizumab-treated patients with inflammatory bowel disease may predict response after dose optimisation
Year: 2018
Source: ECCO '18 Vienna
Authors:

C. Gouynou1, L. Pouillon1,2*, H. Rousseau3, C. Zallot1, C. Baumann3, L. Peyrin-Biroulet1

Created: Thursday, 21 February 2019, 9:14 AM
P440: First results of the BELCOMID study: BELgian Cohort study of COVID-19 in Immune Mediated Inflammatory Diseases (IMID)
Year: 2021
Source: ECCO'21 Virtual
Authors: Geldof, J.(1,2);Truyens, M.(1,2);Sabino, J.(3,4);Ferrante, M.(3,4);Lambert, J.(5);Lapeere, H.(5);Hillary, T.(6);Van Laethem, A.(6);De Vlam, K.(7);Verschueren, P.(7);Lobaton, T.(1,2);Vermeire, S.(3,4);
Created: Wednesday, 2 June 2021, 4:12 PM
P440: Loss of response and dose escalation of infliximab and adalimumab in Ulcerative Colitis patients: A Systematic Review and Meta-analysis.
Year: 2022
Source: ECCO'22
Authors: Savelkoul, E.(1);Thomas, P.(1);Derikx, L.(1);Den Broeder, N.(1);Römkens, T.(2);Hoentjen, F.(3);
Created: Friday, 11 February 2022, 3:52 PM
P440: Prevalence of NUDT15 polymorphisms and incidence of thiopurine-induced leukopenia in Inflammatory Bowel Disease patients: A systematic review and meta-analysis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Yu, N.(1);Sriranganathan, D.(2);Walker, G.J.(3);Sazonovs, A.(4);Wilding, H.(5);Kennedy, N.A.(6,7);Ahmad, T.(6,7);Boyapati, R.K.(8,9);Segal, J.P.(10,11);Ding, N.J.S.(1,11)*;
Created: Friday, 14 July 2023, 11:05 AM
P440: Staged surgical management of complicated ileo-colonic Crohn’s Disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

A. P. Mishreki*, F. G. Bergin

Created: Friday, 22 February 2019, 9:49 AM
P440: Therapeutic drug monitoring of infliximab for the management of loss of response in inflammatory bowel disease: an observational multicenter study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Pugliese D.*1, Armuzzi A.1, Panici Tonucci T.1, Tolusso B.2, Felice C.1, Papa A.1, Cantoro L.3, Balestrieri P.4, Civitelli F.5, Bertani L.6, Kohn A.3, Cicala M.4, Viola F.5, Costa F.6, Rapaccini G.L.1, Guidi L.1

Created: Wednesday, 20 February 2019, 10:36 AM
P441 Efficacy of biosimilar infliximab CT-P13 among inpatients with severe steroid-refractory colitis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

J. Ollech1, I. Normatov2, S. Dwadasi2, S. Dalal2, D. Micic2, A. Israel2, J. Labas2, P. Joel2, R. Cohen2, D. Rubin2, S. Atsushi2

Created: Thursday, 30 January 2020, 10:12 AM
P441: Adalimumab versus ustekinumab as first-line biological in a real-life cohort of moderate-to-severe Crohn's disease.
Year: 2022
Source: ECCO'22
Authors: Moens, A.(1);Verstockt, B.(1);Alsoud, D.(2);Sabino, J.(1);Ferrante, M.(1);Vermeire, S.(1);
Created: Friday, 11 February 2022, 3:52 PM
P441: Clinical efficacy, drug sustainability and results from therapeutic drug monitoring in Crohn’s disease patients treated with ustekinumab – 1-year follow-up of a prospective, nationwide, multicenter cohort from Hungary
Year: 2021
Source: ECCO'21 Virtual
Authors: Gonczi, L.(1);Szanto, K.(2);Farkas, K.(2);Molnar, T.(2);Szamosi, T.(3);Schafer , E.(3);Golovics, P.(3);Lovasz, B.(1);Patai, A.(4);Vincze, A.(5);Sarlos, P.(5);Farkas, A.(6);Dubrovcsik, Z.(6);Tóth G., T.(7);Lakatos, P.L.(8);Miheller, P.(9);Ilias, A.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P441: Conjoint analysis for quantification of inflammatory bowel disease patients’ preferences for outcome metrics
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

W. K. van Deen*1, D. Nguyen1, N. Duran1, E. Kane1, M. G. van Oijen2, D.W. Hommes1

Created: Friday, 22 February 2019, 9:49 AM